First patient enrolled in the project’s clinical study

First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile

• The first patient with type 2 diabetes mellitus (T2D) and diabetes-related complications has been enrolled in a clinical trial called DAPAN-DIA in Basel, Switzerland, with Olatec’s NLRP3 inhibitor, dapansutrile, which is sponsored by Principal Investigator, Marc Donath MD
  
  
• This Phase 2 randomized study is designed to evaluate dapansutrile’s efficacy and safety in approximately 300 patients with elevated blood glucose, systemic inflammation and at risk for complications of diabetes, despite use of standard-of-care anti-diabetic therapy
  
  
• DAPAN-DIA represents the first T2D clinical trial of any selective NLRP3 inhibitor in the emerging class that will also assess cardiometabolic and other risk factors beyond anti-hyperglycemic effects including weight lowering efficacy in combination with GLP-1 therapy
  
  
• The trial is being funded by a consortium that includes Olatec, the European Union under the Horizon Europe Programme (GA No 101095433) and the Swiss Government as part of the INTERCEPT-T2D initiative

Please read more in the press release

More about the DAPAN-DIA study